Drugs / DWC202314
Trials 3
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 11 trial | ||||||
| Phase 1 | NCT06119958 | Oct → Dec 2023 | — | Daewoong Pharmaceutical Co. LTD. | Unknown | No outcome recorded |
| Phase 32 trials | ||||||
| Phase 3 | NCT06671392 | Feb 2025 → Feb 2026 | essential hypertension | Daewoong Pharmaceutical Co. LTD. | Completed | No outcome recorded |
| Phase 3 | NCT06682000 | Jan → Oct 2025 | essential hypertension | Daewoong Pharmaceutical Co. LTD. | Completed | No outcome recorded |
Evidence & citations 2 cited values
Every value below carries the sentence it was read from. 3 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | DWC202314 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT06119958 ↗ |
| Route | Oral | “Multiple Oral Dosings” NCT06119958 ↗ |